Human CD34⁺-derived plasmacytoid dendritic cells as surrogates for primary pDCs and potential cancer immunotherapy.

ABSTRACT:

Introduction

Plasmacytoid dendritic cells (pDCs) are capable of triggering broad immune responses, yet, their scarcity in blood coupled to their reduced functionality in cancer, makes their therapeutic use for in situ activation or vaccination challenging.

Methods

We designed an in vitro differentiation protocol tailored for human pDCs from cord blood (CB) hematopoietic stem cells (HSCs) with StemRegenin 1 (SR-1) and GM-CSF supplementation. Next, we evaluated the identity and function of CB-pDCs compared to human primary pDCs. Furthermore, we tested the potential of CB-pDCs to support anti-tumor immune responses in co-culture with tumor explants from CRC patients.

Results

Here, we report an in vitro differentiation protocol enabling the generation

SUBMITTER: Fiore G 

PROVIDER: S-EPMC11578708 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature